NKP-1339
- Product Name
- NKP-1339
- CAS No.
- 197723-00-5
- Chemical Name
- NKP-1339
- Synonyms
- IT-139;CS-2765;KP 1339;NKP-1339;NKP 1339,NKP1339;NKP-1339 (IT-139;BOLD-100 (NKP-1339);BOLD-100 (NKP-1339, IT-139, KP-1339);KP1339;KP 1339;NKP1339;NKP 1339;KP-1339;Sodium (OC-6-11)-tetrachlorobis(1H-indazole-κN2)ruthenate(1-)
- CBNumber
- CB62628194
- Molecular Formula
- C14H12Cl4N4NaRu
- Formula Weight
- 502.14365
- MOL File
- 197723-00-5.mol
NKP-1339 Property
- storage temp.
- Store at -20°C
- solubility
- Ethanol: soluble
- form
- A solid
- color
- Light brown to khaki
N-Bromosuccinimide Price
- Product number
- SML3505
- Product name
- KP1339
- Purity
- ≥98% (elemental analysis)
- Packaging
- 5MG
- Price
- $220
- Updated
- 2026/03/19
- Product number
- SML3505
- Product name
- KP1339
- Purity
- ≥98% (elemental analysis)
- Packaging
- 25MG
- Price
- $880
- Updated
- 2026/03/19
- Product number
- CS-3474
- Product name
- NKP-1339
- Packaging
- 5mg
- Price
- $420
- Updated
- 2021/12/16
- Product number
- CS-3474
- Product name
- NKP-1339
- Packaging
- 50mg
- Price
- $1800
- Updated
- 2021/12/16
- Product number
- CS-3474
- Product name
- NKP-1339
- Packaging
- 10mg
- Price
- $600
- Updated
- 2021/12/16
NKP-1339 Chemical Properties,Usage,Production
Uses
BOLD-100 (NKP-1339; IT-139) is the first-in-class ruthenium-based anticancer agent in development against solid cancer with limited side effects. BOLD-100 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. BOLD-100 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu[1].
in vivo
BOLD-100 (intravenous injection; 30 mg/kg; once a week; 42sdays) combines with the multi-kinase inhibitor sorafenib and exhibits a further anticancer activity when compares to the BOLD-100 treatment alone in Hep3B xenografts grown in Balb/c SCID mice [2].
| Animal Model: | Hep3B xenograft in Balb/c mice[2] |
| Dosage: | 30 mg/kg |
| Administration: | Intravenous injection |
| Result: | Had synergistic activity of KP1339 with sorafenibin vivo. |
References
[1] Robert Trondl, et al. NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chemical Science. Chemical Science
[2] Heffeter P, et al. The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. Eur J Cancer. 2013 Oct;49(15):3366-75. DOI:10.1016/j.ejca.2013.05.018
NKP-1339 Preparation Products And Raw materials
Raw materials
Preparation Products
NKP-1339 Suppliers
- Tel
- 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
- Fax
- +86-27-87599188
- Country
- China
- ProdList
- 1493
- Advantage
- 55
- Tel
- 021-52996696，15000506266 15000506266
- Fax
- +86-21-52996696
- Country
- China
- ProdList
- 4827
- Advantage
- 55
- Tel
- 21-619849051-1 18521059765
- synchempharma@aliyun.com
- Country
- China
- ProdList
- 4963
- Advantage
- 55
- Tel
- Fax
- -
- eric_feng1954@126.com
- Country
- China
- ProdList
- 9248
- Advantage
- 55
- Tel
- 020-61288194 61288195
- Fax
- 020-61288700
- 505721671@qq.com
- Country
- China
- ProdList
- 3866
- Advantage
- 58
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 86249
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 7999
- Advantage
- 62
- Tel
- 010-60605840 18892239720
- Fax
- 010-60605840
- psaitong@jm-bio.com
- Country
- China
- ProdList
- 12306
- Advantage
- 58
- Tel
- 021-54338626 18017892860
- Fax
- 021-54338626
- sales@tubepharm.com
- Country
- China
- ProdList
- 2657
- Advantage
- 58
- Tel
- 021-34625901 18018851262;
- 420970979@qq.com
- Country
- China
- ProdList
- 5919
- Advantage
- 58